Following adults with advanced cancer using wearable devices and health data
Studies whether personal, genetic and lifestyle traits relate to how advanced cancer responds to treatment.
Plain-language title generated from the registry record
Registry title: High Definition Medicine for Solid Tumors Oncology
Key facts
- Where
- A Coruña, Barcelona, Cáceres, Fuenlabrada, Madrid, Palma de Mallorca, Pamplona, Seville, and Valencia, SpainSee the 9 sites
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with advanced solid cancer (stage III or IV) who are about to start their first treatment aimed at easing the disease, not removing it. Participants wear a device and answer questionnaires.
- Age
- 18 years or older
- Sex
- Women only
- Disease stage
- Confirmed solid cancer at advanced stage (III or IV), not able to have treatment meant to remove all of the disease. The trial gives preference to hormone-positive, HER2-negative breast cancer, lung cancer and colon cancer.
- Earlier treatment
- No earlier treatment for metastatic disease or with the aim of easing the disease. The person is about to start first-line treatment. Treatment inside a clinical trial is allowed if the treatment is known.
- Biomarker or test result
- Hormone-positive, HER2-negative breast cancer is preferred, for women who will receive a CDK4/6 inhibitor plus a hormone inhibitor.
Main reasons for not taking part
- Earlier cancer treatment for metastatic disease or to ease the disease
- Planned treatment in a double-blind trial
- Another past or current cancer that could affect the study results (some skin and cervical cancers treated successfully are allowed)
- Other illness that greatly interferes with taking part, as the investigator decides
- Pacemaker, defibrillator or cardiac resynchronizer
Read by machine on 12 November 2026.
Where in Spain
- Hospital Universitario A CoruñaA Coruña, SpainContact: Rosario Garcia Campelo, MDTaking people
- ICO Hospitalet BellvitgeBarcelona, SpainContact: Sonia Pernas, PhDTaking people
- Hospital San Pedro Alcántara de CáceresCáceres, SpainContact: Santiago Gonzalez, MDTaking people
- Hospital Universitario de FuenlabradaFuenlabrada, SpainContact: Miguel A Quintela, PhDTaking people
- Hospital de La PrincesaMadrid, SpainContact: Ramón Colomer, PhDTaking people
- Hospital Son EspasesPalma de Mallorca, SpainContact: Josefa Terrasa, PhDTaking people
- Complejo Hospitalario de NavarraPamplona, SpainContact: Ruth Vera, PhDTaking people
- Hospital Virgen de la MacarenaSeville, SpainContact: David Vicente, PhDTaking people
- Hospital General de ValenciaValencia, SpainContact: Begoña Bermejo de las Heras, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Centro Nacional de Investigaciones Oncologicas CARLOS III
- Trial code
- NCT06590506
- Record updated
- 19 September 2024
- Original description
The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their possible relationship with tumor response or tolerance to treatment. In this way, the aim is to identify a series of variables that allow a better selection of patients and oncological treatments.Read full original descriptionShow less
High Definition Medicine: Establishment of a Cohort of Patients With Advanced Cancer for Prospective High-resolution Follow-up
The present study aims to analyze different genetic, phenotypic, environmental, social and lifestyle characteristics of cancer patients who are going to start a first line of cancer treatment with palliative intent and their possible relationship with tumor response or tolerance to treatment. In this way, the aim is to identify a series of variables that allow a better selection of patients and oncological treatments.
Inclusion: Confirmed diagnosis of oncological disease of solid origin, candidate for first-line treatment (TREATMENT VIRGIN FOR METASTIC DISEASE); Advanced tumor stage (III or IV) not a candidate for treatment with curative intent; Preference will be given to the following pathologies and sub-types:; Women with hormone-positive, HER2-negative breast cancer who will receive a CDK4/6 inhibitor plus a hormone inhibitor. o Women with lung cancer of any subtype, candidates to receive first-line treatment; Women with colon cancer of any subtype, candidates to receive first-line treatment; Patients who are going to start treatment in a clinical trial are allowed, as long as the treatment is known (in other words, patients who participate in double-blind studies would not be candidates). There are no inclusion problems for patients who have different types of therapies within the trial as long as they are known (examples such as the following, but not limited to these: women starting treatment for breast cancer with a SERD and an approved CDK4/6 inhibitor , women who start an AI and an experimental CDK4/6/2, women who start a triplet for breast cancer but include AI+CDK4/6i, women who start a triplet for lung cancer with chemotherapy, pembrolizumab, and an experimental immunotherapy , etc); ECOG performance status <2; Sufficient capacity and knowledge to carry and use the wearable; Have a mobile device with internet access and an email account; Ability to complete quality of life, nutrition and mental health questionnaires; Written informed consent to participate in the trial obtained prior to any study-specific screening procedures; Patients with co-morbidities are not excluded - they are part of the "real world" clinic and it is necessary to know their evolution; For the same reason, pregnant women are not excluded.
Exclusion: Having previously received oncological treatment for metastatic disease or with palliative intent; Previous or concomitant malignant disease of any other type that could affect compliance with the protocol or interpretation of results. Patients with curatively treated basal cell carcinoma of the skin or cervical cancer in situ are eligible for the study; Concurrent illnesses that may significantly interfere with participation in the study at the discretion of the investigator. No specific diseases are specified, since patients with multiple pathologies are part of the daily clinic and it is very interesting to collect data from patients with other comorbidities, as long as they have the necessary digital familiarization to wear the wearable and use the APP; Carriers of therapeutic electronic devices: pacemakers, defibrillators or cardiac resynchronizers (due to potential interference caused by the device); Planned participation in treatment in a double-blind trial regime.